GPR183 mediates the capacity of the novel CD47-CD19 bispecific antibody TG-1801 to heighten ublituximab-umbralisib (U2) anti-lymphoma activity
M. Ribeiro, N. Profitos-Peleja, J. C. Santos, P. Blecua, D. Reyes Garau, M. Armengol, M. Fernandez-Serrano, H. P. Miskin, F. Bosch, M. Esteller, E. Normant, G. Roue
This study shows that TG-1801 enhances ublituximab's anti-lymphoma activity through GPR183-mediated mechanisms in B-NHL models.
bioRxiv · Mar 31, 2022 · PreprintCancer Biology